Highlights of This Issue 4417

SPECIAL FEATURES

CCR Translations

4419 TP53 Mutations and Lung Cancer: Not All Mutations Are Created Equal
Ramaswamy Govindan and Jason Weber
See related article, p. 4647

4422 “Companion Diagnostics”: Has Their Time Come and Gone?
Fred R. Hirsch, Paul A. Bunn Jr, and Roy S. Herbst
See related article, p. 4488

CCR New Strategies

4425 New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs
Juliane M. Jürgensmeier, Joseph P. Eder, and Roy S. Herbst

CCR Perspectives in Drug Approval

4436 FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Molecular Pathways

4442 Molecular Pathways: Targeting ETS Gene Fusions in Cancer
Felix Y. Feng, J. Chad Brenner, Maha Hussain, and Arul M. Chinnaiyan

CANCER THERAPY: CLINICAL

4449 Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

4459 p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses
Nicola R. Hardwick, Mary Carroll, Teodora Kaltcheva, Dajun Qian, Dean Lin, Lucille Leong, Peiguo Chu, Joseph Kim, Joseph Chao, Marwan Fakih, Yun Yen, Jonathan Espenschied, Joshua D.L. Ellenhorn, Don J. Diamond, and Vincent Chung

4471 Phase I Safety and Pharmacodynamic of Inecalitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients
Jacques Medioni, Gae Deplandeau, Jean-Marc Ferrero, Tristan Maurina, Jean-Michel P. Rodier, Eric Raymond, Jorge Allyon, Gerard Maruani, Pascal Houiller, Sarah Mackenzie, Stephanie Renaux, Jean-Francois Dufour-Lamartine, Reza Elaidi, Celine Lerest, and Stephane Oudard

PERSONALIZED MEDICINE AND IMAGING

4478 Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non–Small Cell Lung Cancer
Christiane Amendt, Eike Staub, Manja Friese-Hämmer, Stephan Störkel, and Christopher Stroh

4488 Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
See related commentary, p. 4422
Alet-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy

Zenia Saridaki, Joanne B. Weidhaas, Heinz-Josef Lenz, Pierre Laurent-Puig, Bart Jacobs, Jef De Schutter, Wendy De Roock, David W. Salzman, Wu Zhang, Dongyun Yang, Camilla Pilati, Olivier Bouché, Hubert Piessevaux, and Sabine Teja

FcγRIia and FcγRIIia Polymorphisms and Cetuximab Benefit in the Microscopic Disease

Francesco Sclafani, David Gonzalez de Castro, David Cunningham, Sanna Hulkki Wilson, Clare Peckitt, Jaume Capdevila, Bengt Giămilius, Susana Roselló Kerànen, Andrew Motherspoon, Gina Brown, Diana Tait, Ruwaida Begum, Janet Thomas, Jacqueline Oates, and Ian Chau

Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts


Noninvasive Detection of Glutamate Predicts Survival in Pediatric Medulloblastoma

Martin Wilson, Simrandip K. Gill, Lesley MacPherson, Martin English, Theodoros N. Arvanitis, and Andrew C. Peet

Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH


The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer

Alison Backen, Andrew C. Rencihan, Andrew R. Clamp, Carlo Berzunzi, Cong Zhou, Amit Oza, Selina Bannoo, Stefan J. Scherer, Rosamonde E. Banks, Caroline Dive, and Gordon C. Jayson

Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer

Zhe Zhang, Jinping Wang, Dongmei Ji, Chenchen Wang, Ruijiao Liu, Zheng Wu, Lian Liu, Dan Zhu, Jinjia Chang, Ruixuan Geng, Lei Xiong, Qiangyi Fang, and Jun Li

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

Jutta Deckert, Marie-Cécile Wetzel, Laura M. Bartle, Anna Skatsletskaya, Victor S. Golshicher, François Vallée, Qing Zhou-Liu, Paul Ferrari, Stéphanie Pouzieux, Charlotte Lahoute, Charles Dumontet, Adriana Plesa, Marielle Chiron, Pascale Lejeune, Thomas Chittenden, Peter U. Park, and Véronique Blanc

Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth

Savita Sankar, Emily R. Theisen, Jared Bearss, Timothy Mulvihill, Laura M. Hoffman, Venkatatwamy Sorna, Mary C. Beckerle, Sunil Sharma, and Stephen L. Lessnick

Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002

Sébastien Couraud, Felipe Vaca-Paniagua, Stéphanie Villar, Javier Oliver, Tibor Schuster, Hélène Blanché, Nicolas Girard, Jean Trédaniel, Laurent Guilmelminault, Radv Gervais, Nathalie Prim, Michel Vincent, Jacques Margery, Sébastien Larivé, Pascal Foucher, Bernard Duvert, Maxime Vallée, Florence Le Calvez-Kelm, James McKay, Pascale Messy, Franck Morin, Gérard Zalcman, Magali Olivier, and Pierre-Jean Souquet for the BioCAST/IFCT-1002 investigators
ABOUT THE COVER

The cover shows the crystal structure of the SAR650984-Fab in complex with human CD38 resolved at 1.53 Å resolution. A close-up view of the epitope highlights the interface between human CD38 and SAR650984-Fab, which involves mainly antibody heavy chain CDR loop H3 (yellow) and light chain CDR loops L1, L2 and L3 (green). For details, see the article by Deckert and colleagues on page 4574 of this issue.